Traditional microbiologic paradigms are straightforward and easy to under stand and apply, but they likely oversimplify what actually occ urs in the midst of an infection. Paradigms for infections of the ear are no exce ption. Ear infections are the most common reason for which antibiotics are prescribed for child ren in the United States, and they attract as much or more researc h attention as other infections do. Although research has answere d many questions about ear infections, it has raised many, as well. Overall, we understand very little about the microbia l community dynamics that underlie these infections .
New theories are being proposed to explain the natural history of otitis media that depar t from the traditional "drug-bug" paradigms. One such theory posits that otitis media is a biofilm disease. Much less study has been co nducted on biofilms in the context of otitis media than with other chronic infectious diseases. Even though data on biofilms in otitis media are rapidly accumulating, we still do not understand very much about them as they may or may not apply to otitis media in all of its forms. Similarly, we do not understand much about microbial community dynamics in general.
Thi s article summarizes what we curre ntly do understand about the microbial community dyn amics of otitis media-otitis media with effusion (OME) and chronic suppurative otitis media (CSOM) in particul ar. Much of the discussion challen ges the biofilm theory of otitis media while providing alternative explanations.
Is OME a biofilm disease-or even an infectious disease?
Wh ile some experts believe that OME is a biofilm disease, others do not believe that it is an infectious disease at all. Support for the noninfectious nature of OME is provided by the fact that only about one-third of middle ear effusions cultured in patients who are diagnosed with OME contain pathogens; the remaining two-th irds are "s terile."!" Even a test as sophisticated as the polymerase chain reaction assay identifies bacterial DNA and mRNA in only 60 to 70% of cases.' When one compares these figures with the rates of culture positivity (range : 44 to 85%) in purulent effusions taken from patients with acute otitis media (AOM), which is clearly felt to be an infectious disease, the overl ap keeps us from reaching any clear conclusion.'
As is the case with other infections, isolated organisms in OME need to be defined as pathogenic or nonpathogenic. Merely isolatin g one of the three primary causative path ogens for AOM (e.g ., nontypeable Ha emophilus infiu en zae [NTHi] or its DNA and associa ted mRN A) is by no means proof positive that the fluid fro m which it was isolated is infected. NTHi is known to be a common commensal organism of the upper aerod igest ive tract. Some authors have descri bed this organism as a hum an airway "m utualist," which in and of itself does not mean that it is a disease -causing pathogen. There is no question that nonencapsulated NTHi (unlike its encapsulated type B counterpart) does not always act as an overt pathoge n that invariably causes invasive disease. Instead, it is often isolate d in asymp tomatic carriage states only posing as an opportunistic threat of causing infections such as pneumonia, sinusitis, and otitis media. Mere ly isolating this pathogen, its DNA, or the mRNA that codes for its expressed proteins does not prove that OME is an infectious disease. So, if it is true that OME is not an infectious disease, any discussion about whether it is or is not a biofilm disease is moot.
Finally, theAmericanAcademy of Otolaryngology-Head and Neck Surgery, the American Academ y of Pediatrics, and the Amer ican Academ y of Family Physicians have agree d that antibiotic treatment is actually contraindicated for patients with OME .3
Can bacteria sur vive ind ependent of a biofilm?
For the sake of discussio n, let us assume that OME is an infectious disease. In that case, is the persiste nce of NTHi in the effusion explained only by the fact that NTHi is protected by a phenotypic switch between a biofilm state and a free-floati ng (planktonic) state? The answer is no. The surface of NTHi is covered with lipooligosaccharide (LOS) endotoxi ns that lack a repeating "0 side chain." Instead, the LOS glycoforms-which are different in terms of their leng th, content, and the nature of their chem ical linkages-include antigen ic structures similar to host cell-surface glycolipids ; they may also contain the host membra ne constituents sialic acid and phosphorylcholine. Therefore, the host' s immune system does not eradicate the organism because it esse ntially "sees" the colonizing orga nism as "se lf."! LOS is also the primary target of the Toll-like receptor 4 pathway that mediates protection. It is important to unde rstand that these mechanisms ex ist, that they enable NTHi to survive despite antibiotic exposure, and that they may or may not be expressed in a biofilm phe notype.
There are several other examples ofthe same concept, but suffice it to say that the concl usio n remains the sa methe host immune sys tem does not eliminate the bac teria beca use the bacteria "tric ks" it into thinking it is self.
Does bacterial per sistence despit e "appropriate" antibiotic use imply a biofilm mechanism of resistanc e? Alth ough this top ic is beyond the sco pe of this articl e and is a subject unto itself, the answe r agai n is no. Independent of the evo lution of biofilm theory, we have long recogni zed that trad ition al drug-bug pa radigms that dem onstrate in vitro susceptibility represent a considerable oversi mplification of that which occ urs in vivo. Ebert and Craig have nicely modeled pharmacokinetic and pharmacodynamic parameters that pred ict bactericidal activity in vivo .'
Far mo re complex and less we ll understood are the dynamics at play between the three main arms of the "bacterial eradication" equation-namely, antibiotics, the host immune response, and bacterial interfe rence .Although on the surface these concepts may seem to be discrete and somewhat mutually exc lusive, the reality is that they are more interrelated than mos t realize. For example, once bacterial load reac hes a certain poi nt, it is unrealistic to bel ieve that any antibiot ic strategy can be dosed such that the antibiotic alone ca n co mpletely eradica te that pathogen. Similarly, in many cases, a host immune respon se is mount ed in an immunocomp etent person eve n before the infecti on is sym ptomatic. Where one can draw the line between a pathogen that persists seco ndary to that bacteria being " res istant" to antibiotics and a pathogen that persists because it tricks the host imm une response into thin king it is se lf is unclear. It is know n, however, that both are needed to effectively eradica te ma ny invadi ng pathoge ns. Even co mpromise of a local immune defense results in " pers istence" of "pathoge ns" (ofte n called "co lonization" in this setti ng) when the very same antibio tic regimen, know n to effectively eradicate that infection in a patient lacking that alteration, is used in the compromised individ ual. One example is colo niza tion ofthejej unum in vagotomized patients who are IgA-d eficient,6This state leads to intractable diarrhea that is not readily treated with antibio tics (and, in fact, often worsens), whereas patients wit hout these co mpro mises of local immunity are effectively cured of diarrhea ca used by the same pathogens. Now, does this "refractory" con dition to antibiotics occur because those bacteria transitioned into a biofilm phenotype or because antibiotics alone were not able to eradicate the pa thoge ns when they lacked the ass istance of two other key host immune fac tors? Although both possi bly play a role, the lack of host imm une res ponse ca n and also does tota lly acco unt for the observed persistence of the disease.
The failure of the overwhelming majority of OME cases "to persist" is another strike against the argument that it is a biofilm disease.
Refractoriness to antibiotics can clearly occur secondary to an interruption in the natural order of bacteri al interfere nce-again, a mech anism ca pable of functioning independ entl y of a biofilm theory. Briefly (using the exa mple of gro up A Streptococcus in the pharynx), when an antibiotic is selected that not only has activity against this pathoge n but also agai nst the typical norm al flora that co lonize the pharynx, competitive inhibitory forces conferred by these "interferi ng bacteria" are eased for the pat hogen as a res ult of the antib iotic erad ication of a substantia l port ion of the normal flora population, as well. Th us, the pathogen surv ives desp ite the use of an antibiotic that is predicted in vitro to be effec tive-not secondary to tra nsitio n into a biofilm state , but secondary to the loss of competitive inhibitory pressure fro m other pathoge ns. (This subject is discusse d in greater det ail and reference d later in this article.)
Fin ally, it is clear that co-pat hoge nicity and co-aggregation allow bacteria pred icted in vitro to be susceptible to a give n antibiotic to survi ve. Co-path ogenicity refers to the fact that a given bacteria surv ives treatment with an antibiotic to which it is susce ptible in vitro because a seco nd bacteria produces an enzyme that confers resistance to that antibiotic. For exa mple, one ofte n observes the persistence of gro up A Streptococcus in the phary nx or tonsil after penic illin treatment because of the concomitant presence of beta-lactamase-producing Bacteroides spp.? Co-aggregation is see n when a pathoge n, such as Streptococcus pyogenes, co lonizes overlapping regions of the human pharynx with a second pathogen such as Moraxella catarrhalis. Th is results in a dramatic increase in S pyogenes adherence to human epithelial cells. This species-specific co-aggregation of these bac teria correlates with the enhanced adherence. The net effec t is obse rve d resistance to penicillin.FThese are clearly mechanisms that can more than ex plain the persis tence of bacteria despite the use of an anti biotic to which it shou ld be susce ptible and independent of a biofil m mec hanism.
Th ese are but a few potential mechani sms to ex plain antibio tic treatment failure despite in vitro susceptibility testin g that would pred ict otherw ise.Thi s author grants that fewer hard data are ava ilab le supporting these alternative mechanisms to exp lain persistence of infection desp ite antibiotic use for otit is media and that these mechanisms may act in concert with biofilm form ation . At the end of the day, howe ver, the fact rema ins that these mecha nisms may just as well be mutually exclusive exp lanations.
Does the presence of a biofilm indicate a biofilm disease?
Does the identification of a biofilm in OME by scanning electron microscopy or by more sophisticated modaliti es prove that OME is a biofilm disease? Agai n, the answer is no. Some 99% of all bacteria ex ist in a biofilm state. ' Qu ite simply, where there are bacteria, there are biofilms. There is continu ous tran sitioning between biofilm and planktonic phenot ypes; therefore, basic science resea rch directed at identifying the factors that affec t the transition is sure to be revealing.
Identifyi ng a biofilm might seem to be a straig htforward process, but it can be challenging because tradit ional diagnostic techniques require the removal ofthe surface to which the biofilm is adhere nt (e.g., an implant or tympanostomy tube), which is not practical in many situations. Even in cases where a middle ear muco sal biopsy is obtainable, it is still far less idea l than a dev ice or implant itself, as most devices and imp lants can be scraped and tissue usually canno t. For most tissue type s, sonication is needed to remove bacteria fro m cells prior to culture. As a result , prov ing that otitis medi a is a biofilm disease (since we are dealing with a liquid effusio n medium and/or tissue) is less certa in than pro ving the existence of a biofilm on an implant.
Other means of attempting to "prove" that diseases like otitis media are biofilm diseases, short of the above-mentioned gold-standard approac h, are being explored: For example, it is promi sing that uniqu e biofilm products are being isolated and that the ratios of intercellul ar signals in biofilms versus planktonic bacte ria are provi ding supportive evidence for the existence of biofilm. Even with this evidence , however, it is a veritable scientific leap to presume that becau se of persistent infection despite adeq uate antibiotic therapy, the conditio n must indeed represent a biofilm disea se. Clearly, as mentio ned earlier, that would be predic ated on the condition itself being an infect ious disease, a concept that is anything but cer tain in the case of OME. Furthermore, "persistence" of infection is a relative term that many do not fee l fairly charac terizes the natural history of OME. Th is, too, calls into serious question whether OME can conclusively be said to be a biofilm disease .
Is OME a persistent infection?
Persistence is one of the hallm arks of classic biofilm dis eases. Consider cys tic fibrosis as an example. If one 10' Volume 86 • Suppl 1 were to exa mine the surface of the airway mucosa in a patie nt with cystic fibrosis every 2 years, the basic pathophysiologic state would be the same. In other words, the co nditio n persists.
However, many challenge whether one can conclude that OME is "persistent" based on its well-know n natural history. Instead, most experts consider it to be self-limited ; about 75 to 90% of residual cases of OME after an AOM episode resolve spontaneously within 3 months.v'? The rate of spontaneous resolution would likely increase even more with longer follow-u p. Therefore, the failure of the overwhelming majority ofOMEcases "to persist" is another strike against the argument that it is a biofilm disea se.
Hydrops ex vacuo: Have we forgotten?
Wh at about the minority of cases of OME that do not spontaneously resolve and do not respond to antibiotic therapy? Do they represent rare exa mples of a small subpopulation of OME patients who actu ally do have a biofilm disease? Or are other pathophysiologic mechanisms in play independent of a biofilm that would explai n these cases ?
Clearly, the latter is true. The literature is repl ete with ev idence that supports the traditional "hydrop s ex vacuo" theory-to wit, OME is caused by obstruction of the eustachian tube without any bacterial involvement.I I Virtually all of Koch 's postulates have been met in defense ofthis theory; such a statement canno t be made for any other proposed pathoph ysiologic mechani sm that underlies OME .
Th e found ation of the hydrops ex vacuo theory is that occ lusion of the eustachi an tube results in certain gasexc hange transition s that incite the express ion of an inflammat ory mediator cascade that is quit e consistent with OME. When the obstruction reso lves, so does the OME . If the obstruction recur s, the OME recur s, as well. Thi s time-h onored theor y explains OME quite nicely-both the rules and the except ions.Thi s is not to say that other path ophysiologic mechani sms may not be involved. However, in our quest to furth er scie ntific know ledge , the evide nce is too strong for us to "fo rget" as we face the temptation to embrace that which is new and "sexy."
Biofilms in normal ears
Does the fact that biofilms are foun d in normal health y ears dimi nish their significance as a pathogen? I was involved in an anima l study in whic h we found biofilms or their phenotypic varia nts, small-co lony variants, in normal ears." Not only were these ears uninfected, they exhibited no gro ss or histologic ev ide nce of mucosal inflamm ation and no inflammatory effusion. The presence of a biofilm had no effect on these ears.
A biofilm disease without detachment
There are five stages involved in the development of biofilm s. The first four may or may not be compatibl e with the theory that otitis media is a biofil m disease. The fifth stage ofbiofilm deve lopment, detac hment, raises yet another challenge in the quest to concl ude that otitis med ia is a biofilm disease. The differe nces in external detachment forces between otitis media and well-charac terized biofilm diseases (e.g ., cystic fibrosis , dental plaque, and dev ice-associated infections) cast more doubt on the theory that OME is a biofilm disease. It makes sense intuitively that these other biofilm diseases could readily include in the Iifecycle of the biofilm itse lf a stage of detachm ent. Conv ersely, it is difficult to conceive of a means by which detachm ent can occur in OME or any form of otitis medi a for that matter. Until goo d ev idence is produc ed dem onstrating that detachm ent occ urs in otitis medi a, this stands as yet another reason we still cannot conclude that it is, in fact, a biofilm disease.
Is CSOM a biofilm disease?
Many authors believe that CSOM is more likely than OME to be a biofi lm disease. In many respec ts, the natur al history of CSOM is consistent with that of a biofilm disease; CSOM is persis tent and generally does not resolve spontaneo usly. Also , unlike most cases of OME, CSO M is a culture -posi tive disease. Finally, not only are there solid animal data" to sup port a role for a biofilm mechanism in CSO M, Coates " has reported a biofilm in a hum an with CSO M. Furthermore, a biofilm phenotype has been show n in vitro.
On the other hand , there is one significant aspec t of CSOM that argues aga inst its being a biofilm disease: More than 90% of CSOM cases respond to antibiotics." Finally, we do not yet know whether a dry ear is a cured ear or if it is merely a surrogate marker of the phenotypic transition from plankt onic state to biofilm state.
Bacterial interference in otitis in general
Despite the plausibilit y of many counterarg uments, let us ass ume that OME meets the primary definition of an infec tious disease. Furth er, let us consider only cases that are, in fact, culture-posi tive and that are also impervious to appropriate antibiotic therapy-that is, thera py predicted in vitro to be bactericidal to plankto nic phenotypes. Would a biofilm theory have to be employed to exp lain this phenomenon ? The answe r, aga in, is 110.
Bacterial interference is a concept that is gai ning support as an alternative to biofilms as an exp lanation for bacterial persis tence in the face ofapprop riate antibiotic treatment.A simplified definition ofbacterial interference is a microbial com munit y dynamic wherein the prese nce of certain bac-: teria interferes with the grow th and survivability of other species.Take the example ofgro upAstreptococci survivi ng on tonsil s despite administration of penicillin , to which they are alm ost always susce ptible in vitro. Some authors believe that as peni cillin attacks the group A streptococc i, it also elimi nates alpha-hemolytic strep tococc i and others, whic h are primary inhibitors of group A streptococci. As a result , bacterial interference is disrupted, treatment fails, and the infection persists . This process may be completely independent of a biofilm mechanism .
Th e same scenario occ urs with methicillin-resistant Stap hylococcus aureus (MRSA) and methicillin-sensitive S aure us (MS SA), both of which co mpe te for residence within the nasal vestibule. The presence ofMSSAi nterferes with the ability of MRS A to establish itself within the nasal vestibule.IS Similar dynamics occ ur in the nasopharynx and likely, by exten sion throu gh the eustachian tube, in the middl e ear cleft.
Although the idea that biofilms playa role in the pathogenesis of any type of otitis media is intriguing and warrants further study, there is no conclu sive evidence to date that they do.
The concep t of bacterial interference argues against the use of broader-and broader-spectrum antibiotics whe n manag ing patients with infec tions such as MRS A. Instead , it dem ands that physicians pay as much attention to what they should not treat as they do to what they should treat. If bacteri al interference affec ts outco mes as much as some suspect, we will see more emphasis bein g placed on avoiding antibiotics that eliminate the inte rfering "good bacteria."
Conclusion
We still have much to learn about the pathophysiology of otit is media in general and about OME and CSO M in particular. Although the idea that biofilms playa role in the pathogenesis of any type of otitis media is intrig uing and warra nts further study, there is no conclusive ev idence to date that they do. While there are good arguments for and against CSOM being a biofilm disease, the evide nce against OME is strong. To reca p:
• Only abou t one-third of middle ear effusions cultured in patients who are diagnosed with OME con tain pathogens; the rem ainin g two-third s are sterile.
• Merely isolating a pathogen from middl e ear fluid does not mean that the fluid is infec ted .
• Th e identificati on of a biofilm in OME by scanning electron microscop y or by more sophisticated modaliti es does not prove that OME is a biofilm disease.
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• Persistence is not a character istic of OME. About 75 to 90 % of residual cases of OME after an AOM episode resolve spontaneously within 3 month s.
• OME may be caused simply by obstruction of the eustachian tube with out any bact eri al involv ement.
• Biofilms are found in norm al healthy ear s. • The differences in extern al detachm ent forc es between otiti s medi a and well-characterized biofilm diseases cast more doubt on the theory that OME is a biofilm disease.
Investigator s who think "o utside the bo x" should be encouraged . However, any recommendation that clinical deci sions should be based on the biofilm theory are very premature.
Thomas Jefferson said it well: "It is always better to have no idea s, than false one s; to believe nothing, than to believe what is wrong."!"
Then again, perhaps Albe rt Einstein said it better: "I think and think for months and years. Ninety-nine time s, the conclusion is false. The hundredth time I am right.?"
